Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + pegylated interferon alpha
- Development stage
- Phase 4
- Lead developer
- Bristol Myers Squibb
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral (entecavir), Subcutaneous (pegylated Interferon Alpha)
01
Overview
**Entecavir + pegylated interferon alpha** is a combination drug regimen used primarily for the treatment of chronic hepatitis B virus (HBV) infection. **Entecavir** is a nucleoside analog that inhibits hepatitis B virus DNA polymerase, leading to suppression of viral DNA replication. **Pegylated interferon alpha** (either alfa-2a or alfa-2b) is a recombinant protein modified for longer half-life; it binds interferon alpha/beta receptors, activating the JAK/STAT pathway and inducing transcription of genes involved in the innate antiviral response, as well as immunomodulation. The combination is intended to offer synergistic effects: entecavir provides potent viral suppression while interferon boosts host immune response, aiming for higher rates of hepatitis B surface antigen (HBsAg) clearance and a functional cure. Combination therapy is used especially in pediatric and selected adult populations.
- Other names
- entecavirpeginterferon alfa-2apeginterferon alfa-2bpegylated interferon alpha
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on entecavir + pegylated interferon alpha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + pegylated interferon alpha.